Abstract:N6-methyladenosine (m6A) is a dynamic posttranscriptional RNA modification that plays an important role in determining transcript fate. The functional consequence of m6A deposition is dictated by a group of host proteins that specifically recognize and bind the m6A modification, leading to changes in RNA stability, transport, splicing, or translation. The cellular m6A methylome undergoes changes during certain pathogenic conditions such as viral infections. However, how m6A modification of host cell transcripts and noncoding RNAs change during severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection has not been reported. Here, we define the epitranscriptomic m6A profile of SARS-CoV-2-infected human lung epithelial cells compared to uninfected controls. We identified mRNA and long and small noncoding RNA species that are differentially m6A modified in response to SARS-CoV-2 infection. The most significantly differentially methylated transcript was the precursor of microRNA-4486 (miRNA-4486), which showed significant increases in abundance and percentage of methylated transcripts in infected cells. Pathway analyses revealed that differentially methylated transcripts were significantly associated with several cancer-related pathways, protein processing in the endoplasmic reticulum, cell death, and proliferation. Upstream regulators predicted to be associated with the proteins encoded by differentially methylated mRNAs include several proteins involved in the type-I interferon response, inflammation, and cytokine signaling. IMPORTANCE Posttranscriptional modification of viral and cellular RNA by N6-methyladenosine (m6A) plays an important role in regulating the replication of many viruses and the cellular immune response to infection. We therefore sought to define the epitranscriptomic m6A profile of human lung epithelial cells infected with SARS-CoV-2. Our analyses demonstrate the differential methylation of both coding and noncoding cellular RNAs in SARS-CoV-2-infected cells compared to uninfected controls. Pathway analyses revealed that several of these RNAs may be involved in the cellular response to infection, such as type-I interferon. Our study implicates m6A modification of infected-cell RNA as a mechanism of posttranscriptional gene regulation during SARS-CoV-2 infection.

Emerging role of N6-methyladenosine RNA modification in regulation of SARS-CoV-2 infection and virus-host interactions

The emerging roles of N6-methyladenosine RNA methylation in human cancers

N6-methyladenosine modification—a key player in viral infection

Regulation of Antiviral Immune Response by N6-Methyladenosine of mRNA

Recent insights into N 6 -methyladenosine during viral infection

M6a Methylation: a Potential Key Player in Understanding and Treating COVID-2019 Infection

The regulation of antiviral innate immunity through non-m6A RNA modifications

Pathogenic Roles of M6a Modification in Viral Infection and Virus-Driven Carcinogenesis.

Pathogenic Roles of m6A Modification in Viral Infection and Virus-driven Carcinogenesis

The Roles of N6-Methyladenosine Modification in Plant-RNA Virus Interactions

Regulation of Virus Replication and T Cell Homeostasis by N6-Methyladenosine

Epitranscriptomics of SARS-CoV-2 Infection

Regulation of Virus Replication and T Cell Homeostasis by N 6 -Methyladenosine

N6-methyladenosine and viral infection

The m6A methylome of SARS-CoV-2 in host cells

Epitranscriptomic N6-Methyladenosine Profile of SARS-CoV-2-Infected Human Lung Epithelial Cells

Decoding epitranscriptomic regulation of viral infection: mapping of RNA N6-methyladenosine by advanced sequencing technologies

The Regulatory Role of N6‐methyladenosine Modification in the Interaction Between Host and Microbes

N 6 -Methyladenosine and Its Implications in Viruses

N6-methyladenosine regulates RNA abundance of SARS-CoV-2

The role of N6-methyladenosine modification in the life cycle and disease pathogenesis of hepatitis B and C viruses